Valuation: Cognition Therapeutics, Inc.

Market Cap 87.97M 78.48M 73.11M 66.54M 125M 8.47B 126M 883M 344M 4.32B 330M 323M 13.9B P/E 2026 *
-3.18x
P/E 2027 * -4.29x
Enterprise Value 87.97M 78.48M 73.11M 66.54M 125M 8.47B 126M 883M 344M 4.32B 330M 323M 13.9B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
98.71%
Yield 2026 *
-
Yield 2027 * -
1 day+1.41%
1 week+0.17%
Current month-2.28%
1 month-8.92%
3 months-19.82%
6 months+8.08%
Current year-30.51%
1 week 0.89
Extreme 0.89
0.99
1 month 0.89
Extreme 0.89
1.08
Current year 0.55
Extreme 0.5501
1.76
1 year 0.55
Extreme 0.5501
2.05
3 years 0.22
Extreme 0.222301
3.83
5 years 0.22
Extreme 0.222301
13.8
10 years 0.22
Extreme 0.222301
13.8
Manager TitleAgeSince
Chief Executive Officer 66 27/03/2020
Director of Finance/CFO 48 01/05/2023
Chief Tech/Sci/R&D Officer - 01/01/2024
Director TitleAgeSince
Director/Board Member 46 01/07/2015
Director/Board Member 69 01/09/2016
Director/Board Member 66 01/03/2019
Date Insider Type Main position Quantity % Market Cap. Importance
01/05/26 Tax

Chief Financial Officer

-8,567 0.0096%
16/04/26 Buy

Chief Executive Officer

9,175 0.0103%
16/04/26 Buy

Chief Financial Officer

10,000 0.0112%
Change 5-day change 1-year change 3-year change Capi.($)
+1.41%+0.17%-39.48%-31.53% 87.97M
+4.16%+3.04%+49.37%+94.17% 74.16B
-0.37%-3.88%+19.75%+78.35% 57.39B
+1.63%+0.98%+3.83%+38.21% 47.64B
+0.50%+1.32%+344.62%+753.25% 44.29B
+3.05%-1.58%+28.78%+35.46% 42.5B
+1.00%+0.22%+5.17%+113.80% 40.71B
-0.54%+2.93%+9.31%+54.06% 30.97B
+1.56%+4.53%+31.34%+26.92% 28.53B
+0.76%-0.89%-7.44%-11.43% 24.34B
Average +1.29%-0.65%+44.52%+115.13% 39.06B
Weighted average by Cap. +1.52%-0.84%+58.04%+140.71%

Financials

2026 *2027 *
Net sales - -
Net income -27.17M -24.24M -22.58M -20.55M -38.7M -2.62B -38.98M -273M -106M -1.34B -102M -99.79M -4.29B -54.95M -49.02M -45.67M -41.56M -78.27M -5.29B -78.85M -552M -215M -2.7B -206M -202M -8.68B
Net Debt - -
Logo Cognition Therapeutics, Inc.
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. The Company is investigating its lead candidate, zervimesine (CT1812), in clinical programs in dementia with Lewy bodies (DLB) and Alzheimer’s disease. Its CT1812 and pipeline of sigma-2 modulators can regulate pathways that are impaired in these diseases for the treatment of degenerative diseases. Its lead product candidate, CT1812, is an orally delivered, small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins. Its pipeline candidates were discovered using proprietary biology and chemistry platforms designed to identify novel drug targets and disease-modifying therapies that address dysregulated pathways. It is developing other product candidates in the area of synucleinopathies.
Employees
14
Date Price Change Volume
06/10/26 $0.9381 +1.41% 325,768
02/10/26 $0.9251 +3.80% 302,399
01/10/26 $0.8912 -7.17% 792,157
30/09/26 $0.9600 +0.59% 386,198
29/09/26 $0.9544 +1.71% 526,509
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.9251USD
Average target price
3.333USD
Spread / Average Target
+260.32%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CGTX Stock